{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:32:00Z","timestamp":1784097120526,"version":"3.55.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although dyspnoea is the most common cause of admission for acute heart failure (AHF), more needs to be known about its clinical course and prognostic significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The Pre-RELAX-AHF study randomized 232 subjects with AHF to placebo or four doses of relaxin and evaluated early (6\u201324 h Likert scale) and persistent [change in visual analogue scale area under the curve (VAS AUC) through Day 5] dyspnoea relief. Worsening heart failure (WHF) was defined as worsening AHF signs and symptoms requiring additional therapy. Patients were followed until Day 180. Early dyspnoea relief was observed in only 25% of all patients, and VAS AUC at 5 days was 45% over baseline values in all patients (32% placebo; 50% all relaxin-treated patients). Worsening heart failure to Day 5 was observed in 16% of all patients (21% placebo; 14% relaxin). Lack of persistent dyspnoea relief and WHF were associated with a longer length of initial hospital stay and worse 60-day outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dyspnoea relief in patients admitted with AHF is often incomplete, and many may show WHF after the initial stabilization. Both lack of persistent dyspnoea relief and in-hospital WHF predict a longer length of stay and worse outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfq132","type":"journal-article","created":{"date-parts":[[2010,8,23]],"date-time":"2010-08-23T21:31:18Z","timestamp":1282599078000},"page":"1130-1139","source":"Crossref","is-referenced-by-count":87,"title":["Dyspnoea and Worsening Heart Failure in Patients with Acute Heart Failure: Results from the Pre-RELAX-AHF Study"],"prefix":"10.1093","volume":"12","author":[{"given":"Marco","family":"Metra","sequence":"first","affiliation":[{"name":"Cardiology, Department of Experimental and Applied Medicine, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of California , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Felker","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry H.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"University of California, San Diego Medical Center , San Diego, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Athens University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Department of Heart Diseases, Medical University, Clinical Military Hospital , Wroc\u0142aw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam L.","family":"Teichman","sequence":"additional","affiliation":[{"name":"Corthera, Inc. (part of Novartis Pharmaceutical Corp.) , San Carlos, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Unemori","sequence":"additional","affiliation":[{"name":"Corthera, Inc. (part of Novartis Pharmaceutical Corp.) , San Carlos, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen , Groningen ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Davison","family":"Weatherley","sequence":"additional","affiliation":[{"name":"Momentum Research Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[{"name":"Momentum Research Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,13]]},"reference":[{"key":"2026020203331230900_ejhfhfq132-bib-0001","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0002","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jacc.2008.10.041","article-title":"Acute heart failure syndromes","volume":"53","author":"Gheorghiade","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026020203331230900_ejhfhfq132-bib-0003","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"2009 Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026020203331230900_ejhfhfq132-bib-0004","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejheart.2007.04.003","article-title":"Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology","volume":"9","author":"Metra","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0005","first-page":"1531","article-title":"Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","author":"Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF)","year":"2002","journal-title":"JAMA"},{"key":"2026020203331230900_ejhfhfq132-bib-0006","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"2026020203331230900_ejhfhfq132-bib-0007","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"2026020203331230900_ejhfhfq132-bib-0008","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cardfail.2004.08.160","article-title":"Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry","volume":"11","author":"O'Connor","year":"2005","journal-title":"J Card Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0009","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacc.2005.09.022","article-title":"Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database","volume":"47","author":"Yancy","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026020203331230900_ejhfhfq132-bib-0010","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.jacc.2007.02.037","article-title":"Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure","volume":"49","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026020203331230900_ejhfhfq132-bib-0011","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cardfail.2008.08.010","article-title":"The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment","volume":"14","author":"Cotter","year":"2008","journal-title":"J Card Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0012","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurheartj\/ehp458","article-title":"The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study","volume":"31","author":"Mebazaa","year":"2010","journal-title":"Eur Heart J"},{"key":"2026020203331230900_ejhfhfq132-bib-0013","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/eurheartj\/ehq015","article-title":"Evaluating dyspnoea in acute heart failure: progress at last!","volume":"31","author":"Hogg","year":"2010","journal-title":"Eur Heart J"},{"key":"2026020203331230900_ejhfhfq132-bib-0014","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1472-8206.2009.00697.x","article-title":"Early worsening heart failure in patients admitted with acute heart failure\u2014a new outcome measure associated with long-term prognosis?","volume":"23","author":"Weatherley","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"2026020203331230900_ejhfhfq132-bib-0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000249280","article-title":"Physician-Determined Worsening Heart Failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure\u2014association with signs and symptoms, hospitalization duration, and 60-day outcomes","volume":"115","author":"Cotter","year":"2009","journal-title":"Cardiology"},{"key":"2026020203331230900_ejhfhfq132-bib-0016","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cardfail.2009.04.001","article-title":"Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome","volume":"15","author":"Torre-Amione","year":"2009","journal-title":"J Card Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejheart.2005.12.003","article-title":"Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE","volume":"8","author":"Cleland","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0018","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejheart.2008.01.002","article-title":"Overview of emerging pharmacologic agents for acute heart failure syndromes","volume":"10","author":"De Luca","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0019","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"key":"2026020203331230900_ejhfhfq132-bib-0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10741-008-9127-5","article-title":"Vasodilators in the treatment of acute heart failure: what we know, what we don't","volume":"14","author":"Metra","year":"2009","journal-title":"Heart Fail Rev"},{"key":"2026020203331230900_ejhfhfq132-bib-0021","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jama.293.5.572","article-title":"Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis","volume":"293","author":"Fonarow","year":"2005","journal-title":"JAMA"},{"key":"2026020203331230900_ejhfhfq132-bib-0022","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ahj.2008.04.030","article-title":"Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in-Hospitalized Patients with Heart Failure (OPTIMIZE-HF)","volume":"156","author":"O'Connor","year":"2008","journal-title":"Am Heart J"},{"key":"2026020203331230900_ejhfhfq132-bib-0023","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/eurjhf\/hfq002","article-title":"Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure","volume":"12","author":"Harjola","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0024","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.jacc.2008.08.028","article-title":"Changing preferences for survival after hospitalization with advanced heart failure","volume":"52","author":"Stevenson","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 2","key":"2026020203331230900_ejhfhfq132-bib-0025","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1067\/mhj.2003.151","article-title":"Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure","volume":"145","author":"Teerlink","year":"2003","journal-title":"Am Heart J"},{"key":"2026020203331230900_ejhfhfq132-bib-0026","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ahj.2009.04.010","article-title":"Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group","volume":"157","author":"Gheorghiade","year":"2009","journal-title":"Am Heart J"},{"key":"2026020203331230900_ejhfhfq132-bib-0027","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/eurheartj\/ehn048","article-title":"A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach","volume":"29","author":"Pang","year":"2008","journal-title":"Eur Heart J"},{"key":"2026020203331230900_ejhfhfq132-bib-0028","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1093\/eurheartj\/ehp253","article-title":"Effects of tolvaptan on dyspnoea relief from the EVEREST trials","volume":"30","author":"Pang","year":"2009","journal-title":"Eur Heart J"},{"key":"2026020203331230900_ejhfhfq132-bib-0029","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejheart.2008.01.007","article-title":"Fluid overload in acute heart failure\u2013re-distribution and other mechanisms beyond fluid accumulation","volume":"10","author":"Cotter","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejheart.2006.06.004","article-title":"Acute heart failure associated with high admission blood pressure\u2014a distinct vascular disorder?","volume":"9","author":"Milo-Cotter","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0031","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cardfail.2008.07.188","article-title":"Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF)","volume":"14","author":"Allen","year":"2008","journal-title":"J Card Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0032","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/eurjhf\/hfq021","article-title":"Dyspnoea in Patients with Acute Heart Failure. An analysis of its clinical course, determinants and relationship to 60 day outcomes in the PROTECT pilot study","volume":"12","author":"Metra","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0033","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","article-title":"Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial","volume":"9","author":"Hasselblad","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026020203331230900_ejhfhfq132-bib-0034","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1388-9842(02)00041-7","article-title":"The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis","volume":"4","author":"Thackray","year":"2002","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfq132","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/12\/10\/1130\/66497724\/eurjhf_12_10_1130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/12\/10\/1130\/66497724\/eurjhf_12_10_1130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:33:23Z","timestamp":1770021203000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/12\/10\/1130\/8433825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,1]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,1,13]]},"published-print":{"date-parts":[[2010,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfq132","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,10]]},"published":{"date-parts":[[2010,10,1]]}}}